<p>argenx SE（纳斯达克代码：ARGX - 获取免费报告）获得了目前覆盖该公司的二十三家研究机构的共识评级为 “买入”，Marketbeat Ratings 报告称。一位研究分析师给予该股票持有评级，二十位分析师给予买入评级，另外两位分析师给予强烈买入评级。在过去一年中，更新了对该股票覆盖的经纪商的平均一年目标价为 698.11 美元。</p>
<ul>
<li>5 只医疗股票的收益增长达到三位数</li>
</ul>
<p>ARGX 成为多份研究报告的主题。花旗集团在 5 月 14 日的研究报告中重申了对 argenx 股票的 “跑赢大盘” 评级。富国银行将 argenx 股票的目标价从 723.00 美元上调至 741.00 美元，并在 2 月 28 日的研究报告中给予该公司 “增持” 评级。古根海姆将 argenx 股票的目标价从 1,100.00 美元下调至 1,065.00 美元，并在 5 月 9 日的研究报告中对该股票给予 “买入” 评级。Wedbush 在 4 月 11 日的研究报告中重申了 “跑赢大盘” 评级，并将 argenx 股票的目标价设定为 715.00 美元。最后，桑福德·C·伯恩斯坦在 3 月 17 日的研究报告中将 argenx 股票的评级从 “市场表现” 上调至 “跑赢大盘”。</p>
<p><strong>查看我们关于 argenx 的最新报告</strong></p>
<h2>机构资金流入和流出</h2>
<ul>
<li>Argenx 的 28% 激增和有前景的产品提升了投资者信心</li>
</ul>
<p>一些机构投资者和对冲基金最近对该公司的持仓进行了调整。FMR LLC 在第四季度将其在 argenx 股票中的持股比例提高了 17.2%。FMR LLC 现在拥有 5,618,222 股该公司股票，价值 3,455,207,000 美元，在此期间又购买了 824,750 股。Capital World Investors 在第四季度将其在 argenx 股票中的持股比例提高了 5.1%。Capital World Investors 现在拥有 1,786,936 股该公司股票，价值 1,099,002,000 美元，在此期间又购买了 86,687 股。RTW Investments LP 在第四季度将其在 argenx 股票中的持股比例提高了 2.9%。RTW Investments LP 现在拥有 673,497 股该公司股票，价值 414,201,000 美元，在此期间又购买了 19,067 股。Clearbridge Investments LLC 在第四季度将其在 argenx 股票中的持股比例提高了 6.8%。Clearbridge Investments LLC 现在拥有 629,828 股该公司股票，价值 387,344,000 美元，在此期间又购买了 40,330 股。最后，Jennison Associates LLC 在第四季度将其在 argenx 的持仓增加了 27.0%。Jennison Associates LLC 现在拥有 302,149 股该公司股票，价值 185,821,000 美元，在上个季度又购买了 64,183 股。对冲基金和其他机构投资者持有该公司 60.32% 的股票。</p>
<h2>argenx 股价上涨 1.1%</h2>
<p>ARGX 股票周四开盘价为 584.95 美元。argenx 的 1 年最低价为 358.80 美元，1 年最高价为 678.21 美元。该公司的 50 日简单移动平均线为 590.90 美元，200 日简单移动平均线为 612.98 美元。该公司的市值为 357.2 亿美元，市盈率为-664.72，贝塔系数为 0.57。</p>
<p>argenx（纳斯达克代码：ARGX - 获取免费报告）最近在 5 月 8 日公布了季度财报。该公司报告季度每股收益（EPS）为 2.58 美元，超出市场共识预期的 2.32 美元，超出幅度为 0.26 美元。该公司季度收入为 13.5 亿美元，而分析师预期为 7.4834 亿美元。argenx 的净利润率为-2.11%，股本回报率为-1.45%。股票研究分析师预计，argenx 在当前财政年度将发布 3.13 美元的每股收益。</p>
<h2>关于 argenx</h2>
<p>（获取免费报告）</p>
<p>argenx SE 是一家生物技术公司，致力于开发各种治疗自身免疫疾病的疗法，覆盖美国、日本、欧洲、中东、非洲和中国。其主要产品候选药物是 efgartigimod，用于治疗重症肌无力、免疫性血小板减少症、天疱疮、广泛性重症肌无力、慢性炎症性脱髓鞘性多发性神经病、甲状腺眼病、疱疹性皮肤病、肌炎、原发性干燥综合症、后新冠姿势性心动过速综合症、膜性肾病、狼疮性肾病、ANCA 相关性血管炎和抗体介导的排斥反应；ENHANZE SC；Empasiprubart 用于多灶性运动神经病、延迟移植物功能和皮肌炎；以及 ARGX-119 用于先天性重症肌无力综合症和肌萎缩侧索硬化症。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 argenx</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>300 亿美元的人工智能机会：它会推动 Meta 的下一次激增吗？</li>
<li>如何使用 MarketBeat 股息计算器</li>
<li>微软可能会在欧盟反垄断案件接近解决时反弹</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>英特尔重新聚焦：NEX 出售和铸造转型标志着新时代的开始</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJHWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 argenx 吗？</h2>
<p>在你考虑投资 argenx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 argenx 并不在名单上。</p>
<p>虽然 argenx 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ARGX

<p>argenx SE（纳斯达克股票代码：ARGX）获得了 23 家研究机构的一致 “买入” 评级。平均目标价格为 698.11 美元，其中包括 1 个持有评级、20 个买入评级和 2 个强力买入评级。最近的报告包括花旗集团的 “跑赢大盘” 评级和富国银行将目标价格上调至 741.00 美元。机构投资者持有该股票的 60.32%，开盘价为 584.95 美元，1 年区间为 358.80 美元至 678.21 美元。公司报告每股收益（EPS）为 2.58 美元，超出预期，并预计本财年的每股收益为 3.13 美元</p>

<p>argenx SE (NASDAQ:ARGX - Get Free Report) has earned a consensus rating of &#34;Buy&#34; from the twenty-three research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, twenty have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $698.11.</p>
<div class="lb-trans"><p>argenx SE（纳斯达克代码：ARGX - 获取免费报告）获得了目前覆盖该公司的二十三家研究机构的共识评级为 “买入”，Marketbeat Ratings 报告称。一位研究分析师给予该股票持有评级，二十位分析师给予买入评级，另外两位分析师给予强烈买入评级。在过去一年中，更新了对该股票覆盖的经纪商的平均一年目标价为 698.11 美元。</p>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗股票的收益增长达到三位数</li>
</ul>
</div><p>ARGX has been the topic of several research reports. Citigroup reiterated an &#34;outperform&#34; rating on shares of argenx in a research report on Wednesday, May 14th. Wells Fargo &amp; Company upped their target price on shares of argenx from $723.00 to $741.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, February 28th. Guggenheim cut their target price on shares of argenx from $1,100.00 to $1,065.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, May 9th. Wedbush restated an &#34;outperform&#34; rating and set a $715.00 target price on shares of argenx in a research report on Friday, April 11th. Finally, Sanford C. Bernstein upgraded shares of argenx from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research report on Monday, March 17th.</p>
<div class="lb-trans"><p>ARGX 成为多份研究报告的主题。花旗集团在 5 月 14 日的研究报告中重申了对 argenx 股票的 “跑赢大盘” 评级。富国银行将 argenx 股票的目标价从 723.00 美元上调至 741.00 美元，并在 2 月 28 日的研究报告中给予该公司 “增持” 评级。古根海姆将 argenx 股票的目标价从 1,100.00 美元下调至 1,065.00 美元，并在 5 月 9 日的研究报告中对该股票给予 “买入” 评级。Wedbush 在 4 月 11 日的研究报告中重申了 “跑赢大盘” 评级，并将 argenx 股票的目标价设定为 715.00 美元。最后，桑福德·C·伯恩斯坦在 3 月 17 日的研究报告中将 argenx 股票的评级从 “市场表现” 上调至 “跑赢大盘”。</p>
</div><p><strong>View Our Latest Report on argenx</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 argenx 的最新报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增和有前景的产品提升了投资者信心</li>
</ul>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC lifted its stake in shares of argenx by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock valued at $3,455,207,000 after purchasing an additional 824,750 shares during the period. Capital World Investors lifted its stake in shares of argenx by 5.1% in the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after purchasing an additional 86,687 shares during the period. RTW Investments LP lifted its stake in shares of argenx by 2.9% in the 4th quarter. RTW Investments LP now owns 673,497 shares of the company's stock valued at $414,201,000 after purchasing an additional 19,067 shares during the period. Clearbridge Investments LLC lifted its stake in shares of argenx by 6.8% in the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock valued at $387,344,000 after purchasing an additional 40,330 shares during the period. Finally, Jennison Associates LLC increased its position in argenx by 27.0% during the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company's stock valued at $185,821,000 after buying an additional 64,183 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近对该公司的持仓进行了调整。FMR LLC 在第四季度将其在 argenx 股票中的持股比例提高了 17.2%。FMR LLC 现在拥有 5,618,222 股该公司股票，价值 3,455,207,000 美元，在此期间又购买了 824,750 股。Capital World Investors 在第四季度将其在 argenx 股票中的持股比例提高了 5.1%。Capital World Investors 现在拥有 1,786,936 股该公司股票，价值 1,099,002,000 美元，在此期间又购买了 86,687 股。RTW Investments LP 在第四季度将其在 argenx 股票中的持股比例提高了 2.9%。RTW Investments LP 现在拥有 673,497 股该公司股票，价值 414,201,000 美元，在此期间又购买了 19,067 股。Clearbridge Investments LLC 在第四季度将其在 argenx 股票中的持股比例提高了 6.8%。Clearbridge Investments LLC 现在拥有 629,828 股该公司股票，价值 387,344,000 美元，在此期间又购买了 40,330 股。最后，Jennison Associates LLC 在第四季度将其在 argenx 的持仓增加了 27.0%。Jennison Associates LLC 现在拥有 302,149 股该公司股票，价值 185,821,000 美元，在上个季度又购买了 64,183 股。对冲基金和其他机构投资者持有该公司 60.32% 的股票。</p>
</div><h2>argenx Trading Up 1.1%</h2>
<div class="lb-trans"><h2>argenx 股价上涨 1.1%</h2>
</div><p>Shares of ARGX stock opened at $584.95 on Thursday. argenx has a 1 year low of $358.80 and a 1 year high of $678.21. The firm's fifty day simple moving average is $590.90 and its 200 day simple moving average is $612.98. The firm has a market capitalization of $35.72 billion, a P/E ratio of -664.72 and a beta of 0.57.</p>
<div class="lb-trans"><p>ARGX 股票周四开盘价为 584.95 美元。argenx 的 1 年最低价为 358.80 美元，1 年最高价为 678.21 美元。该公司的 50 日简单移动平均线为 590.90 美元，200 日简单移动平均线为 612.98 美元。该公司的市值为 357.2 亿美元，市盈率为-664.72，贝塔系数为 0.57。</p>
</div><p>argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.26. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Equities research analysts anticipate that argenx will post 3.13 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>argenx（纳斯达克代码：ARGX - 获取免费报告）最近在 5 月 8 日公布了季度财报。该公司报告季度每股收益（EPS）为 2.58 美元，超出市场共识预期的 2.32 美元，超出幅度为 0.26 美元。该公司季度收入为 13.5 亿美元，而分析师预期为 7.4834 亿美元。argenx 的净利润率为-2.11%，股本回报率为-1.45%。股票研究分析师预计，argenx 在当前财政年度将发布 3.13 美元的每股收益。</p>
</div><h2>About argenx</h2>
<div class="lb-trans"><h2>关于 argenx</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.</p>
<div class="lb-trans"><p>argenx SE 是一家生物技术公司，致力于开发各种治疗自身免疫疾病的疗法，覆盖美国、日本、欧洲、中东、非洲和中国。其主要产品候选药物是 efgartigimod，用于治疗重症肌无力、免疫性血小板减少症、天疱疮、广泛性重症肌无力、慢性炎症性脱髓鞘性多发性神经病、甲状腺眼病、疱疹性皮肤病、肌炎、原发性干燥综合症、后新冠姿势性心动过速综合症、膜性肾病、狼疮性肾病、ANCA 相关性血管炎和抗体介导的排斥反应；ENHANZE SC；Empasiprubart 用于多灶性运动神经病、延迟移植物功能和皮肌炎；以及 ARGX-119 用于先天性重症肌无力综合症和肌萎缩侧索硬化症。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than argenx</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>$30B AI Opportunity: Will It Power Meta’s Next Surge?</li>
<li>How to Use the MarketBeat Dividend Calculator</li>
<li>Microsoft Could Rally as EU Antitrust Case Nears Resolution</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>Intel Refocuses: NEX Sale and Foundry Pivot Signal New Era</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 argenx</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>300 亿美元的人工智能机会：它会推动 Meta 的下一次激增吗？</li>
<li>如何使用 MarketBeat 股息计算器</li>
<li>微软可能会在欧盟反垄断案件接近解决时反弹</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>英特尔重新聚焦：NEX 出售和铸造转型标志着新时代的开始</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJHWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ARGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in argenx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 argenx 吗？</h2>
</div><p>Before you consider argenx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 argenx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 argenx 并不在名单上。</p>
</div><p>While argenx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 argenx 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

argenx SE（NASDAQ 代码：ARGX）被分析师一致推荐为 “买入”